MedTrace Logo

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

NCT00572169 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2026-02-05

No results posted yet for this study

Summary

With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."

Conditions

Interventions

DRUG

Velcade

Will be given in central venous catheter

DRUG

Thalidomide

Capsule taken by mouth

DRUG

Dexamethasone

A pill taken by mouth

DRUG

Adriamycin

Given into the vein (IV) by a continuous infusion through a central catheter

DRUG

Cisplatin

Given into the vein (IV) by a continuous infusion through a central catheter

DRUG

Cyclophosphamide

Given into the vein (IV) by a continuous infusion through a central catheter

DRUG

Etoposide

Given into the vein (IV) by a continuous infusion through a central catheter

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Gareth Morgan, MD, PhD · UAMS Myeloma Institute for Research and Therapy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00572169 on ClinicalTrials.gov